HCL

Showing 1 posts of 1 posts found.

astrazeneca_plaque

FDA approves AstraZeneca’s Lumoxiti for hairy cell leukaemia (HCL)

September 17, 2018
Sales and Marketing AstraZeneca, HCL, Lumoxiti, leukaemia, rare diseases

AstraZeneca’s Lumoxiti has been approved for use for the treatment of relapsed or refractory hairy cell leukemia (HCL)in adults who …

The Gateway to Local Adoption Series

Latest content